Statement: 4 patients in the primary trial experienced a grade 3 or above adverse event.
Primary_evidence: Adverse Events 1:   Total: 16/48 (33.33%)   Febrile neutropenia grade 3 3/48 (6.25%)   Neutropenia grade 3 1/48 (2.08%)   Holocraneal cephalea 1/48 (2.08%)   Hypersensibility reaction grade 3 2/48 (4.17%)   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)   Catheter - related infection grade 3 1/48 (2.08%)